# Cigna Group: Form 10-Q for the period ended Sep 30, 2019

- Company: [Cigna Group](/companies/ci.md) (CIK 1739940)
- Form: 10-Q
- Filed: 2019-10-31
- Accepted by EDGAR: Oct 31, 2019, 12:54 ET
- Period: 2019-09-30
- Accession: 0001739940-19-000012
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1739940/000173994019000012/ci-20190930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1739940/000173994019000012/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $38.56bn | us-gaap:Revenues |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $115.32bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $24.55bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $73.56bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $3.41bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $10.10bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $2.12bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | $6.52bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $409.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $1.17bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $1.35bn | us-gaap:ProfitLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $4.14bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $3.57 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $10.83 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $3.60 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $10.94 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 378,321,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 381,091,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $6.69bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $740.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-30 | $1.54bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-30 | $4.58bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $21.17bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $154.85bn | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $34.45bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $110.11bn | us-gaap:Liabilities |
| Current portion of debt | at 2019-09-30 | $4.71bn | us-gaap:DebtCurrent |
| Short-term borrowings | at 2019-09-30 | $1.14bn | us-gaap:CommercialPaper |
| Shareholders' equity | at 2019-09-30 | $44.70bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 73,550 characters.

|  | PAGE |
| --- | ---: |
| Executive Overview | 52 |
| Liquidity and Capital Resources | 57 |
| Critical Accounting Estimates | 60 |
| Segment Reporting | 60 |
| Health Services | 61 |
| Integrated Medical | 63 |
| International Markets | 64 |
| Group Disability and Other | 65 |
| Corporate | 66 |
| Investment Assets | 66 |

*Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition as of September 30, 2019 compared with December 31, 2018 and our results of operations for the three and nine months ended September 30, 2019 compared with the same periods last year. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018 (“2018 Form 10-K”), in particular the “Risk Factors” contained in Part I, Item 1A of that form.*

*Unless otherwise indicated, financial information in the MD&A is presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). See Note 2 to the Consolidated Financial Statements in our 2018 Form 10-K for additional information regarding the Company’s significant accounting policies and Note 2 to the Consolidated Financial Statements in the Form 10-Q for updates to those accounting policies resulting from adopting new accounting guidance. The preparation of interim consolidated financial statements necessarily relies heavily on estimates. This and certain other factors, such as the seasonal nature of portions of the health care and related pharmacy and other benefits businesses, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations. In some of our financial tables in this MD&A, we present either percentage changes or “N/M” when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points (“bps”).*

*In this MD&A, our consolidated measures “adjusted income from operations,” earnings per share on that same basis, and “adjusted revenues” are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of “shareholders’ net income,” “earnings per share” and “total revenues.” We also use pre-tax adjusted income from operations and adjusted revenues to measure the results of our segments.*

*We use adjusted income from operations as our principal financial measure of operating performance because management believes it best reflects the underlying results of our business operations and permits analysis of trends in underlying revenue, expenses and profitability. We define adjusted income from operations as shareholders’ net income (or income before taxes for the segment metric) excluding realized investment gains and losses, amortization of acquired intangible assets, results of Anthem, Inc. and Coventry Health Care Inc. (“Coventry”) (collectively, the “transitioning clients”) (see the “Key Transactions and Developments” section of the MD&A for further discussion of transitioning clients) and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Income or expense amounts excluded from adjusted income from operations because they are not indicative of underlying performance or the responsibility of operating segment management include:*

*Realized investment gains (losses) including changes in market values of certain financial instruments between balance sheet dates, as well as gains and losses associated with invested asset sales.*

*Amortization of acquired intangible assets because these relate to costs incurred for acquisitions.*

*Results of transitioning clients because those results are not indicative of ongoing results.*

*Special items, if any, that management believes are not representative of the underlying results of operations due to the nature or size of these matters. See Note 18 to the Consolidated Financial Statements for descriptions of special items.*

*Adjusted revenues is defined as total revenues excluding the following adjustments: revenue contributions from transitioning clients, special items and Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting.*

### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; the merger (“Merger”) with Express Scripts Holding Company; and other statements regarding Cigna’s future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical and pharmacy costs and price effectively; our ability to adapt to changes or trends in an evolving and rapidly changing industry; our ability to effectively differentiate our products and services from those of our competitors and maintain or increase market share; our ability to develop and maintain good relationships with physicians, hospitals, other health care providers and pharmaceutical manufacturers; changes in drug pricing; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits (including anticipated synergies) of such transactions in full or within the anticipated time frame, including with respect to the Merger, as well as our ability to integrate operations, resources and systems; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and/or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; the impact of our debt service obligations on the availability of funds for other business purposes; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; as well as more specific risks and uncertainties discussed in Part I, Item 1A – Risk Factors and Part II, Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our 2018 Form 10-K and as described from time to time in our future reports filed with the Securities and Exchange Commission (the “SEC”).

You should not place undue reliance on forward-looking statements that speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

### EXECUTIVE OVERVIEW

Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as “Cigna,” the “Company,” “we,” “our” or “us”) is a global health service organization dedicated to a mission of helping those we serve improve their health, well-being and peace of mind. Our evolved strategy in support of our mission is ***Go Deeper, Go Local, Go Beyond*** using a differentiated set of pharmacy, medical, dental, disability, life and accident insurance and related products and services offered by our subsidiaries. For further information on our business and strategy, see Item 1, “Business” in our 2018 Form 10-K.

As described more fully in Note 4 to the Consolidated Financial Statements, on December 20, 2018, we completed the acquisition of Express Scripts Holding Company (“Express Scripts”) and changed our segments effective in the fourth quarter of 2018. See Note 1 to the Consolidated Financial Statements for a description of our segments. As described further in Note 2 to the Consolidated Financial Statements, we adopted Article 5 of Regulation S-X issued by the SEC effective December 31, 2018. Prior year information presented in this Form 10-Q was restated to reflect these changes. In addition, as discussed in Note 18 to the Consolidated Financial Statements, effective in the first quarter of 2019, compensation cost for stock options is now recorded by our segments. Prior year segment information has not been restated for this change. Results for the three and nine months ended September 30, 2019 included the results of Express Scripts’ business, whereas results for the three months and the nine months ended September 30, 2018 reflected only Cigna’s stand-alone historical results. Unless otherwise specified, the commentary provided below describes our results for the three and nine months ended September 30, 2019 compared with the same periods in 2018.

Summarized below are certain key measures of our performance by segment for the three months and the nine months ended September 30, 2019 and 2018:

*Financial highlights by segment*

*(Dollars in millions, except per share amounts)*

| Revenues Adjusted revenues by segment | Three Months Ended September 30, 2019 | 2018 | % Change | Nine Months Ended September 30, 2019 | 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Health Services | **$24,880** | $1,109 | N/M | **$70,877** | $3,293 | N/M |
| Integrated Medical | **9,148** | 8,174 | 12% | **27,311** | 24,494 | 12% |
| International Markets | **1,402** | 1,326 | 6 | **4,185** | 4,011 | 4 |
| Group Disability and Other | **1,284** | 1,262 | 2 | **3,889** | 3,815 | 2 |
| Corporate, including eliminations | **(881)** | (426) | (107) | **(2,625)** | (1,253) | (109) |
| Adjusted revenues | **35,833** | 11,445 | 213 | **103,637** | 34,360 | 202 |
| Revenue contributions from transitioning clients | **2,718** | - | N/M | **11,657** | - | N/M |
| Net realized investment results from certain equity method investments | **5** | (1) | N/M | **27** | (23) | N/M |
| Special items reported in transaction-related costs | **-** | 13 | N/M | **-** | 13 | N/M |
| Total revenues | **$38,556** | $11,457 | 237% | **$115,321** | $34,350 | 236% |
| **Shareholders’ net income** | **$1,351** | $772 | 75% | **$4,127** | $2,493 | 66% |
| **Adjusted income from operations** | **$1,718** | $945 | 82% | **$4,856** | $2,910 | 67% |
| **Earnings per share (diluted)** |  |  |  |  |  |  |
| Shareholders’ net income | **$3.57** | $3.14 | 14% | **$10.83** | $10.14 | 7% |
| Adjusted income from operations | **$4.54** | $3.84 | 18% | **$12.74** | $11.84 | 8% |
| **Pre-tax adjusted income from operations by segment** |  |  |  |  |  |  |
| Health Services | **$1,399** | $67 | N/M | **$3,555** | $227 | N/M |
| Integrated Medical | **953** | 932 | 2% | **3,113** | 2,859 | 9% |
| International Markets | **194** | 195 | (1) | **607** | 615 | (1) |
| Group Disability and Other | **143** | 143 | - | **376** | 420 | (10) |
| Corporate, including eliminations | **(442)** | (83) | N/M | **(1,385)** | (255) | N/M |
| Consolidated pre-tax adjusted income from operations | **2,247** | 1,254 | 79 | **6,266** | 3,866 | 62 |
| Adjustment for transitioning clients | **274** | - | N/M | **1,589** | - | N/M |
| Income attributable to noncontrolling interests | **4** | 3 | 33 | **13** | 10 | 30 |
| Realized investment gains (losses) | **56** | (1) | N/M | **111** | (59) | N/M |
| Amortization of acquired intangible assets | **(734)** | (48) | N/M | **(2,214)** | (99) | N/M |
| Special items | **(84)** | (175) | 52 | **(456)** | (365) | (25) |
| **Income before income taxes** | **$1,763** | $1,033 | 71% | **$5,309** | $3,353 | 58% |

52

For further analysis and explanation of each segment’s results, see the “Segment Reporting” section of this MD&A beginning on page 60.

*(Dollars in millions)*

| Consolidated Results of Operations (GAAP basis) | Three Months Ended September 30, 2019 | 2018 | % Change | Nine Months Ended September 30, 2019 | 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmacy revenues | **$25,987** | $747 | N/M | **$77,454** | $2,222 | N/M |
| Premiums | **9,935** | 8,994 | 10% | **29,709** | 27,005 | 10% |
| Fees and other revenues | **2,285** | 1,361 | 68 | **7,123** | 4,087 | 74 |
| Net investment income | **349** | 355 | (2) | **1,035** | 1,036 | - |
| **Total revenues** | **38,556** | 11,457 | 237 | **115,321** | 34,350 | 236 |
| Pharmacy and other service costs | **24,552** | 602 | N/M | **73,565** | 1,776 | N/M |
| Medical costs and other benefit expenses | **7,734** | 6,803 | 14 | **22,930** | 20,420 | 12 |
| Selling, general and administrative expenses | **3,413** | 2,872 | 19 | **10,096** | 8,454 | 19 |
| Amortization of acquired intangible assets | **734** | 48 | N/M | **2,214** | 99 | N/M |
| **Total benefits and expenses** | **36,433** | 10,325 | 253 | **108,805** | 30,749 | 254 |
| Income from operations | **2,123** | 1,132 | 88 | **6,516** | 3,601 | 81 |
| Interest expense and other | **(411)** | (99) | N/M | **(1,291)** | (212) | N/M |
| Net realized investment gains (losses) | **51** | - | N/M | **84** | (36) | N/M |
| **Income before income taxes** | **1,763** | 1,033 | 71 | **5,309** | 3,353 | 58 |
| Income taxes | **409** | 259 | 58 | **1,173** | 854 | 37 |
| **Net income** | **1,354** | 774 | 75 | **4,136** | 2,499 | 66 |
| Less: net income attributable to noncontrolling interest | **3** | 2 | 50 | **9** | 6 | 50 |
| **Shareholders’ net income** | **$1,351** | $772 | 75% | **$4,127** | $2,493 | 66% |
| Consolidated effective tax rate | **23.2%** | 25.1% | 190 bps | **22.1%** | 25.5% | 340 bps |
| **Medical customers (in thousands)** |  |  |  |  |  |  |
| Integrated Medical |  |  |  | **15,495** | 15,301 | 1% |
| International Markets |  |  |  | **1,576** | 1,558 | 1 |
| Total |  |  |  | **17,071** | 16,859 | 1% |

*Reconciliation of Shareholders’ Net Income to Adjusted Income from Operations*

*$ in millions*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 | Diluted Earnings Per Share Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| **Shareholders’ net income** | **$1,351** | $772 | $4,127 | $2,493 | **$3.57** | $3.14 | **$10.83** | $10.14 |
| **After-tax adjustments required to reconcile to adjusted income from operations** |  |  |  |  |  |  |  |  |
| - Adjustment for transitioning clients | **(207)** | - | **(1,217)** | - | **(0.55)** | - | **(3.19)** | - |
| - Net realized investment (gains) losses | **(49)** | (1) | **(100)** | 46 | **(0.13)** | - | **(0.26)** | 0.19 |
| - Amortization of acquired intangible assets | **558** | 36 | **1,694** | 74 | **1.47** | 0.15 | **4.43** | 0.30 |
| **Special items** |  |  |  |  |  |  |  |  |
| - Integration and transaction-related costs | **88** | 108 | **311** | 267 | **0.24** | 0.43 | **0.82** | 1.09 |
| - Charges (benefits) associated with litigation matters | **(23)** | 35 | **41** | 35 | **(0.06)** | 0.14 | **0.11** | 0.14 |
| - Charges (benefits) associated with U.S. tax reform | **-** | (5) | **-** | (5) | **-** | (0.02) | - | (0.02) |
| Total special items | **65** | 138 | **352** | 297 | **0.18** | 0.55 | **0.93** | 1.21 |
| **Adjusted income from operations** | **$1,718** | $945 | **$4,856** | $2,910 | **$4.54** | $3.84 | **$12.74** | $11.84 |

53

### Commentary: Three Months and Nine Months Ended September 30, 2019 versus the same periods in 2018

Unless indicated otherwise, the commentary presented below, and in the segment discussions that follow, applies to both the three months and nine months ended September 30, 2019, compared to the same periods in 2018.

### Earnings and Revenue

***Shareholders’ net income*** increased, primarily driven by the earnings contribution from Express Scripts and improved results in the Integrated Medical segment partially offset by interest expense on debt issued to finance the Express Scripts acquisition. Earnings per share also increased, but at a significantly lower rate, reflecting dilution caused by shares issued in connection with the Express Scripts acquisition.

***Adjusted income from operations*** increased, reflecting earnings from Express Scripts’ pharmacy benefits and medical management businesses reported in the Health Services segment and improved results in Integrated Medical. These favorable results were partially offset by higher interest expense reported in Corporate from debt issued to finance the acquisition and assumed from Express Scripts. Adjusted income from operations per share also increased, but at a significantly lower rate, reflecting dilution caused by shares issued in connection with the Express Scripts acquisition.

***Medical customers*** increased, primarily attributable to growth in the Select and Middle Market segments, partially offset by a decline in National Accounts.

***Revenue*** growth largely reflects the addition of Express Scripts and, to a lesser extent, business growth in the Integrated Medical segment. Detailed revenue items are discussed further below.

- ***Pharmacy revenues*** in 2019 reflect the Express Scripts pharmacy benefit management business. See the Health Services Segment section of this MD&A for further discussion of pharmacy revenues.
- ***Premiums*** were higher, primarily resulting from: 1) customer growth across all segments, predominantly Integrated Medical, 2) rate increases in Integrated Medical reflecting underlying medical cost trends; and 3) a contribution from Express Scripts’ Medicare Part D business.
- ***Fees and other revenues.*** The increases were primarily driven by contributions from Express Scripts’ medical management business reported in the Health Services segment. To a lesser extent, higher fees in our Integrated Medical segment primarily driven by growth in our specialty businesses contributed to the increases.
- ***Net investment income*** was essentially flat, as lower yields were substantially offset by higher average assets.

### Other Components of Consolidated Results of Operations

***Pharmacy and other service costs.*** In 2019, this amount is largely comprised of Express Scripts’ pharmacy benefits and medical management businesses reported in the Health Services segment. In 2018, Cigna’s home delivery business comprised the entire amount.

***Medical costs and other benefit expenses*** increased, largely attributable to medical cost inflation in Integrated Medical, customer growth in the insured business and the addition of Express Scripts’ Medicare Part D business.

***Selling, general and administrative expenses*** increased, primarily due to the addition of Express Scripts and, to a lesser extent, volume-related expenses in Integrated Medical. These increases were partially offset by suspension of the health insurance industry tax in 2019.

***Amortization of acquired intangible assets*** in 2019 primarily reflects the impact of the Express Scripts acquisition. See Note 3 in the Consolidated Financial Statements of our 2018 Form 10-K for additional information on the intangible assets identified in the Express Scripts acquisition.

***Interest expense and other*** increased significantly, primarily due to interest incurred on debt issued in the third quarter of 2018 to finance the Express Scripts acquisition along with Express Scripts’ debt assumed upon closing of the acquisition.

***Realized investment gains (losses).*** We reported realized investment gains for the three and nine months ended September 30, 2019, compared with no gain or loss for the three months and losses for the nine months ended September 30, 2018. The improvements largely result from gains on sales of real estate joint ventures in the third quarter of 2019, higher gains on sales of debt securities and favorable market value adjustments on equity securities.

***The consolidated effective tax rate*** declined, primarily due to suspension of the nondeductible health insurance industry tax in 2019 and, for the nine months, recognition of incremental state tax benefits in the second quarter of 2019.

### Key Transactions and Business Developments

### Merger with Express Scripts

As discussed in more detail in our 2018 Form 10-K, Cigna acquired Express Scripts on December 20, 2018 in a cash and stock transaction valued at $52.8 billion. The “Liquidity” section of this MD&A provides further discussion of the impact of the acquisition on our liquidity and capital resources.

We continue to incur costs related to this transaction. These costs are being reported in “integration and transaction-related costs” as a special item and excluded from adjusted income from operations. The results of the Express Scripts’ business were included in Cigna’s consolidated financial information for the three and nine months ended September 30, 2019, whereas the three and nine months ended September 30, 2018 reflected only Cigna’s stand-alone historical results.

On January 30, 2019, Anthem exercised its early termination right and terminated their pharmacy benefit management services agreement with us, effective March 1, 2019. There is a twelve-month transition period ending March 1, 2020. The transition of Anthem’s customers is expected to occur at various dates, as informed by Anthem’s technology platform migration schedule. We will focus on an effective transition of this relationship and related services over Anthem’s accelerated timeline. We exclude the results of Express Scripts’ contract with Anthem (and also Coventry) from our non-GAAP reporting metrics “adjusted revenues” and “adjusted income from operations” and refer to these clients as “transitioning clients.”

### Industry Developments and Other Matters Affecting Our Health Services and Integrated Medical Segments

Our 2018 Form 10-K provides a detailed description of The Patient Protection and Affordable Care Act (“ACA”) provisions and other legislative initiatives that impact our health care and pharmacy services businesses, including regulations issued by the Centers for Medicare & Medicaid Services (“CMS”) and the Departments of the Treasury and Health and Human Services (“HHS”). The health care and pharmacy services businesses continue to operate in a dynamic environment, and the laws and regulations applicable to these businesses, including the ACA, continue to be subject to legislative, regulatory and judicial challenges. The table presented below provides an update on the impact of these items and other matters affecting our Integrated Medical and Health Services segments as of September 30, 2019.

| Item | Description |
| --- | --- |
| **Medicare Advantage** | Medicare Star Quality Ratings (“Star Ratings”): CMS uses a Star Rating system to measure how well Medicare Advantage (“MA”) plans perform, scoring how well plans perform in several categories, including quality of care and customer service. Star Ratings range from one to five stars. CMS recognizes plans with Star Ratings of four stars or greater with quality bonus payments and the ability to offer enhanced benefits. Approximately 73% of our MA customers are in a four star or greater plan for bonus payments to be received in 2019. We expect this percentage to increase to 77% for bonus payments to be received in 2020 and 85% for bonus payments to be received in 2021. |
|  | Risk Adjustment: As discussed in the “Regulation” and “Risk Factors” sections of our 2018 Form 10-K, our MA business is subject to reviews, including risk adjustment data validation (“RADV”) audits by CMS and the Office of the Inspector General (“OIG”). We expect that CMS, OIG and other federal agencies will continue to closely scrutinize components of the Medicare program. The “Regulation” and “Health Care Industry Developments and Other Matters Affecting Our Integrated Medical and Health Services Segments” sections of our 2018 Form 10-K also discuss a proposed rule issued by CMS in 2018 that included, among other things, extrapolation of the error rate related to RADV audit findings without applying the adjustment for underlying fee-for-service data errors as currently contemplated by CMS’s RADV audit methodology. If adopted in its current form, the rule could have a detrimental impact to all MA insurers and affect the ability of plans to deliver high quality health care for the population served. The Company, along with other MA organizations and additional interested parties, submitted comments to CMS on the proposed rule as part of the notice-and-comment rulemaking process. The comment period concluded on August 28, 2019. It is uncertain if CMS will finalize the rule as proposed. Preliminary data validation for CMS contract years 2011 through 2013 audits has been completed and the Company does not expect the impact of the rule, if adopted as proposed, to be material to the Company’s results of operations for these contract years. Data validation for the CMS contract year 2014 audit is in process. As a result, the Company cannot estimate the potential impact of adoption of the proposed rule for contract year 2014 at this time. In addition, the Company is subject to OIG RADV audits that are in process. The U.S. Department of Justice also is currently conducting an industry-wide investigation of risk adjustment data submission practices and business processes, as described in Note 16 to the Consolidated Financial Statements. |

| Item | Description |
| --- | --- |
| **Health Insurance Industry Tax** | Health Insurance Industry Tax: Federal legislation suspended the health insurance industry tax for 2019 and our premium rates for 2019 reflect this suspension. We recorded $94 million for the three months and $279 million for the nine months ended September 30, 2018. Under current legislation, the industry tax will return in 2020 and is expected to approximate $460 million. The return of the industry tax in 2020 is contemplated in our premium rates and benefits for the affected products. |
| **Public Health Exchanges** | Market Participation: In 2019, we are offering individual coverage on the public health insurance exchanges in Arizona, Colorado, Illinois, Missouri, North Carolina, Tennessee and Virginia. For 2020, we are expanding individual exchange offerings into Kansas, Utah and Florida, as well as new counties in Tennessee and Virginia. |
| Cost Sharing Reduction Subsidies: The ACA provides for cost sharing reductions that offset the amount that qualifying customers pay for deductibles, copayments and coinsurance. The federal government stopped funding insurers for the cost sharing reduction subsidies in 2017. Certain insurers have sued the federal government for failure to pay cost sharing reduction subsidies and the matter remains unresolved. To date, judges in six of those actions have ruled in favor of the insurers, three of which are presently under appeal. We will continue to monitor developments. Our premium rates for the 2019 plan year reflected a lack of government funding for cost sharing reduction subsidies. We followed a similar approach for 2020 premium rates. |  |

56

### Risk Mitigation Programs – Individual ACA Business

See the MD&A in our 2018 Form 10-K for background around legal actions related to the risk corridor and risk adjustment programs. During the second quarter of 2019, the U.S. Supreme Court agreed to review the unfavorable lower court rulings in the risk corridor cases. We continue to carry an allowance for the balance of our risk corridor receivables of $109 million. No other significant updates occurred in the third quarter of 2019 related to these risk corridor and risk adjustment legal matters.

In April 2019, CMS published the final Notice of Benefit and Payment Parameters for the 2020 plan year that clarified the 2017 benefit year RADV program. CMS released the 2017 benefit year data validation error rates in May and published the preliminary RADV transfers in August 2019. Based on the information currently available, we adjusted our risk adjustment balance to reflect the expected outcome of the RADV program.

The following table presents our balances associated with the risk adjustment program as of September 30, 2019 and December 31, 2018, inclusive of the RADV adjustments recorded in 2019.

*(In millions)*

| Risk Adjustment | Net Receivable (Payable) Balance September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Receivables (1) | **$57** | $32 |
| Payables (2) | **(174)** | (187) |
| Total risk adjustment balance | **$(117)** | $(155) |
| (1) Receivables, net of allowances, are reported in accounts receivable in the Consolidated Balance Sheets. |  |  |
| (2) Payables are reported in accrued expenses and other liabilities (current) in the Consolidated Balance Sheets. |  |  |

Charges for the ongoing risk adjustment program and RADV audit adjustments were $18 million pre-tax ($14 million after-tax) for the three months and $134 million pre-tax ($103 million after-tax) for the nine months ended September 30, 2019 compared with $48 million pre-tax ($38 million after-tax) and $143 million ($113 million after-tax) for the same periods in 2018.

### LIQUIDITY AND CAPITAL RESOURCES

### Liquidity

We maintain liquidity at two levels: the subsidiary level and the parent company level.

Liquidity requirements at the subsidiary level generally consist of:

medical costs, pharmacy and other benefit payments;

expense requirements, primarily for employee compensation and benefits, information technology and facilities costs; and

income taxes.

Our subsidiaries normally meet their operating requirements by:

maintaining appropriate levels of cash, cash equivalents and short-term investments;

using cash flows from operating activities;

matching investment durations to those estimated for the related insurance and contractholder liabilities;

selling investments; and

borrowing from affiliates, subject to applicable regulatory limits.

Liquidity requirements at the parent company level generally consist of:

debt service and dividend payments to shareholders;

lending to subsidiaries as needed; and

pension plan funding.

The parent company normally meets its liquidity requirements by:

maintaining appropriate levels of cash and various types of marketable investments;

collecting dividends from its subsidiaries;

using proceeds from issuing debt and common stock; and

borrowing from its subsidiaries, subject to applicable regulatory limits.

Dividends from our insurance, Health Maintenance Organization (“HMO”) and foreign subsidiaries are subject to regulatory restrictions. Because most of Express Scripts’ subsidiaries are not subject to regulatory restrictions on paying dividends, Express Scripts’ operations provide significantly increased financial flexibility to Cigna.

Cash flows for the nine months ended September 30 were as follows:

*(In millions)*

|  | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Operating activities | **$6,692** | $3,644 |
| Investing activities | **$(463)** | $(1,674) |
| Financing activities | **$(5,480)** | $19,115 |

The following discussion explains variances in the various categories of cash flows for the nine months ended September 30, 2019 compared with the same period in 2018.

### Operating activities

Cash flows from operating activities consist principally of cash receipts and disbursements for pharmacy revenues and costs, premiums, fees, investment income, taxes, benefit costs and other expenses.

Cash flows from operating activities increased, primarily driven by higher net income adjusted for depreciation and amortization and reduction in inventories. These increases were partially offset by the timing of accounts receivable collections and higher income tax payments.

### Investing and Financing activities

Cash used in investing activities decreased, primarily due to higher proceeds from investment sales coupled with lower investment purchases.

Cash flows from financing activities for the nine months ended September 30, 2018 included $19.9 billion of proceeds from long-term debt issued to fund the Express Scripts acquisition. Excluding this item, cash used in financing activities increased in 2019, primarily due to higher repayments of long-term debt and share repurchases.

We maintain a share repurchase program authorized by our Board of Directors. Under this program, we may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors including price, general business and market conditions and alternate uses of capital. The share repurchase program may be effected through open market purchases or privately negotiated transactions in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans. The program may be suspended or discontinued at any time.

For the nine months ended September 30, 2019, we repurchased 9.3 million shares for approximately $1.5 billion. In October 2019, the Board increased repurchase authority by an additional $1.0 billion. From October 1, 2019 through October 30, 2019 we repurchased 1.5 million shares for approximately $240 million. Share repurchase authority was $1.2 billion as of October 30, 2019.

### Capital Resources

Our capital resources (primarily cash flows from operating activities and proceeds from the issuance of debt and equity securities) provide protection for policyholders, furnish the financial strength to underwrite insurance risks and facilitate continued business growth.

Our acquisition of Express Scripts increased our debt and shareholders’ equity in 2018 as follows:

***Stock.*** Express Scripts’ shareholders received 0.2434 of a share of common stock of Cigna for every one share of Express Scripts’ common stock. Cigna issued 137.6 million additional shares to Express Scripts’ shareholders.

***Debt.*** See Note 6 to the Consolidated Financial Statements for further description of the debt issued to finance the acquisition.

***Assumption of Express Scripts’ Senior Notes.*** See Note 6 to the Consolidated Financial Statements for further description of the notes assumed in the acquisition of Express Scripts.

At September 30, 2019, our debt-to-capitalization ratio was 46.4%, a decline from 50.9% at December 31, 2018. We expect to deleverage to the upper 30s by the end of 2020 using cash flows from operating activities.

In 2018, Cigna entered into a new Revolving Credit Agreement and Term Loan Credit Agreement in financing the Express Scripts acquisition. Cigna had $21 million of letters of credit outstanding under the Revolving Credit Agreement as of September 30, 2019. In the fourth quarter of 2019, Cigna entered into an additional 364-day revolving credit agreement that matures in October 2020. See Note 6 to the Consolidated Financial Statements for further information on our revolving credit agreements and the Term Loan Credit Agreement.

Management, guided by regulatory requirements and rating agency capital guidelines, determines the amount of capital resources that we maintain. Management allocates resources to new long-term business commitments when returns, considering the risks, look promising and when the resources available to support existing business are adequate.

We prioritize our use of capital resources to:

provide the capital necessary to support growth and maintain or improve the financial strength ratings of subsidiaries and to fund pension obligations;

consider acquisitions that are strategically and economically advantageous; and

return capital to investors primarily through share repurchases.

We continue to maintain a capital management strategy to retain overseas a significant portion of the earnings from our foreign operations. These undistributed earnings are deployed outside of the United States predominantly in support of the liquidity and regulatory capital requirements of our foreign operations as well as to support growth initiatives overseas. This strategy does not materially limit our ability to meet our liquidity and capital needs in the United States.

### Liquidity and Capital Resources Outlook

We maintain sufficient liquidity to meet our cash needs through our cash and cash equivalents balances, cash flows from operations, commercial paper program, credit agreements, and the issuance of long-term debt. As of September 30, 2019, we had approximately $4.8 billion in cash and short-term investments, approximately $1.1 billion of which was held by the parent company or nonregulated subsidiaries. We actively monitor our debt obligations and engage in issuance or redemption activities as needed in accordance with our capital management strategy. During the fourth quarter of 2019, we settled a debt exchange that generated additional near-term liquidity through the recognition of current tax losses that will reverse over the remaining life of the debt. A description of our outstanding debt, including further discussion of the debt exchange completed in the fourth quarter of 2019, can be found in Note 6 to the Consolidated Financial Statements.

During the first quarter of 2019, our unfunded pension liability increased by approximately $140 million due to the settlement of the Amara litigation, as described more fully in Notes 13 and 16 to the Consolidated Financial Statements. In addition, our pension liability will be re-measured at December 31, 2019 using updated pension assets and valuation assumptions, including discount rates. As of September 30, 2019, discount rates had declined approximately 110 basis points since December 31, 2018. If year-end discount rates and pension assets were to remain at the levels as of September 30, 2019, our pension liability would increase by approximately $300 million, resulting in an after-tax charge to accumulated other comprehensive income of approximately $240 million. However, we cannot predict the actual amount of the year-end adjustment as it will depend on discount rates activity and investment performance during the fourth quarter of 2019. Our required contributions for 2019 under the Pension Protection Act of 2006 remain unchanged and were immaterial. We currently expect 2020 required contributions to be immaterial. See Note 13 to the Consolidated Financial Statements for additional information regarding our pension plans.

Our cash projections may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the Risk Factors section of our 2018 Form 10-K. Though we believe we have adequate sources of liquidity, significant disruption or volatility in the capital and credit markets could affect our ability to access those markets for additional borrowings or increase costs. In addition to the sources of liquidity discussed above, the parent company can borrow an additional $1.1 billion from its insurance subsidiaries without additional state approval.

### Guarantees and Contractual Obligations

We are contingently liable for various contractual obligations entered into in the ordinary course of business. See Note 16 to the Consolidated Financial Statements for discussion of various guarantees.

We have updated the long-term debt and purchase obligations as of September 30, 2019 previously provided in our 2018 Form 10-K.

*(In millions, on an undiscounted basis)*

| On-Balance Sheet | Total | Less than 1 year (1) | 1-3 years | 4-5 years | After 5 years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Long-term debt (1) | **50,190** | **368** | **9,287** | **9,397** | **31,138** |
| **Off-Balance Sheet** |  |  |  |  |  |
| Purchase obligations | **2,989** | **830** | **1,484** | **558** | **117** |
| (1) Amounts reflect cash obligations for the remainder of 2019 and do not include amounts related to current maturities of long-term debt. See Note 6 to the Consolidated Financial Statements for information regarding our long-term debt. |  |  |  |  |  |

### CRITICAL ACCOUNTING ESTIMATES

The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate to be critical if:

it requires assumptions to be made that were uncertain at the time the estimate was made; and

changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of operations or financial condition.

Management has discussed how critical accounting estimates are developed and selected with the Audit Committee of our Board of Directors and the Audit Committee has reviewed the disclosures presented in our 2018 Form 10-K. We regularly evaluate items that may impact critical accounting estimates. Our most critical accounting estimates, as well as the effect of hypothetical changes in material assumptions used to develop each estimate, are described in the 2018 Form 10-K. As of September 30, 2019, there were no significant changes to the critical accounting estimates from what was reported in our 2018 Form 10-K.

### Goodwill and Other Intangible Assets

Our annual evaluations of goodwill and other intangible assets for impairments were completed during the third quarter of 2019. These evaluations were performed at the reporting unit level, based on discounted cash flow analyses or market data. The estimated fair value of each of our reporting units exceeded their carrying values by sufficient margins.

Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate. However, if actual experience significantly differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our consolidated results of operations, and in certain situations, could have a material adverse effect on liquidity and our financial condition.

### SEGMENT REPORTING

The following section of this MD&A discusses the results of each of our segments. As a result of the Express Scripts acquisition, during the fourth quarter of 2018, we changed our segment reporting to reflect the new management and business reporting structure of the combined company. Prior year segment information presented in this Form 10-Q was restated to conform to the new segment presentation. See Note 1 to the Consolidated Financial Statements for a description of our segments.

In segment discussions, we present adjusted revenues and “pre-tax adjusted income from operations,” defined as income before taxes excluding realized investment gains (losses), amortization of acquired intangible assets, results of transitioning clients and special items. Ratios presented in this segment discussion exclude the same items as pre-tax adjusted income from operations. See Note 18 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income before income taxes to pre-tax adjusted income from operations, as well as a reconciliation of total revenues to adjusted revenues. Note 18 to the Consolidated Financial Statements also explains two additional items that are important in understanding our segment results: 1) segment revenues include both external revenues and sales between segments that are eliminated in Corporate; and 2) beginning in the first quarter of 2019, compensation cost for stock options is recorded by the segments. Prior year segment information was not restated for the change in stock option reporting.

In these segment discussions, we also present “pre-tax adjusted margin,” defined as adjusted income from operations before taxes divided by adjusted revenues.

See the MD&A Executive Overview beginning on page 52 for summarized financial results of each of our segments.

### Health Services Segment

The Health Services segment includes the pharmacy benefit management, pharmacy home delivery and certain medical management services. This segment includes Express Scripts’ business from the December 20, 2018 date of acquisition except for Express Scripts’ Medicare Part D business that is reported in the Government operating segment. This segment also includes Cigna’s legacy mail order pharmacy business. Due to the timing of the acquisition, results of operations for the three months and nine months ended September 30, 2018 did not include results from the Express Scripts’ business. The main driver of period over period increases in the financial information presented below is the inclusion of results from the Express Scripts’ business in 2019. As described in the introduction to Segment Reporting on page 60, performance of the Health Services segment is measured using pre-tax adjusted income from operations.

The key factors that impact Health Services revenues and costs of revenues are volume, mix and price. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements included in our 2018 Form 10-K for additional information on revenue and cost recognition policies for this segment.

As our clients’ claim volumes increase or decrease, our resulting revenues and cost of revenues correspondingly increase or decrease. Our gross profit could also increase or decrease as a result of changes in purchasing discounts.

The mix of claims generally considers the type of drug and distribution method used for dispensing and fulfilling. As our mix of drugs changes, our resulting pharmacy revenues and cost of revenues correspondingly may increase or decrease. The primary driver of fluctuations within our mix of claims is the generic fill rate. Generally, higher generic fill rates reduce revenues, as generic drugs are typically priced lower than the branded drugs they replace. However, as ingredient cost paid to pharmacies on generic drugs is incrementally lower than the price charged to our clients, higher generic fill rates generally have a favorable impact on our gross profit. The home delivery generic fill rate is currently lower than the network generic fill rate as fewer generic substitutions are available among maintenance medications (such as therapies for chronic conditions) commonly dispensed from home delivery pharmacies as compared to acute medications that are primarily dispensed by pharmacies in our retail networks.

Our client contract pricing is impacted by our ability to negotiate supply chain contracts for pharmacy network, pharmaceutical and wholesaler purchasing, and manufacturer rebates. As we seek to improve the effectiveness of our integrated solutions for the benefit of our clients, we are continuously innovating and optimizing the supply chain. Inflation also impacts our pricing because most of our contracts provide that we bill clients and pay pharmacies based on a generally recognized price index for pharmaceuticals. Therefore, the rate of inflation for prescription drugs and our efforts to manage this inflation for our clients can affect our revenues and cost of revenues.

In this MD&A, we present revenues and gross profit “excluding transitioning clients” in addition to those metrics including transitioning clients. Pre-tax adjusted income from operations and pre-tax adjusted margin exclude contributions from transitioning clients. See the “Key Transactions and Developments” section on page 55 of this MD&A for further discussion of transitioning clients and why we present this information.

### Results of Operations

*(In millions)*

| Financial Summary | Three Months Ended September 30, 2019 2018 | Change Favorable (Unfavorable) | Nine Months Ended September 30, 2019 2018 | Change Favorable (Unfavorable) |
| --- | ---: | --- | ---: | --- |
| Total revenues | **$27,598** $1,109 | N/M% | **$82,534** $3,293 | N/M% |
| Less: revenue contributions from transitioning clients | **(2,718)** - | N/M% | **(11,657)** - | N/M% |
| Adjusted revenues | **$24,880** $1,109 | N/M% | **$70,877** $3,293 | N/M% |
| Gross profit | **$2,192** $90 | N/M% | **$6,631** $291 | N/M% |
| Gross profit excluding transitioning clients | **$1,880** $90 | N/M% | **$4,887** $291 | N/M% |
| Pre-tax adjusted income from operations | **$1,399** $67 | N/M% | **$3,555** $227 | N/M% |
| Pre-tax adjusted margin | **5.6%** 6.0% | (40) bps | **5.0%** 6.9% | (190) bps |

*(Dollars and adjusted scripts in millions)*

| Selected Financial Information(1) Pharmacy revenue by distribution channel | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
| --- | ---: | ---: |
| Network revenues | **$10,911** | **$29,937** |
| Home delivery and specialty revenues | **11,650** | **34,198** |
| Other revenues | **1,228** | **3,608** |
| Total pharmacy revenues | **$23,789** | **$67,743** |
| **Pharmacy script volume** |  |  |
| Adjusted network scripts(2) | **242** | **687** |
| Adjusted home delivery and specialty scripts(2) | **70** | **211** |
| Total adjusted scripts(2) | **312** | **898** |
| **Generic fill rate** |  |  |
| Network | **87.1%** | **87.5%** |
| Home delivery | **84.2%** | **84.2%** |
| Overall generic fill rate | **86.7%** | **87.1%** |

#### (1) Amounts exclude contributions from transitioning clients.

*(2) Non-specialty network scripts filled through 90-day programs and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.*

### Three and Nine Months Ended September 30, 2019 versus Three and Nine Months Ended September 30, 2018

This segment includes Express Scripts’ business from the date of acquisition by the Company on December 20, 2018 with the exception of Express Scripts’ Medicare Part D business that is reported in the Government operating segment. In the third quarter of 2019, Integrated Medical’s Commercial customers transitioned to Express Scripts’ retail pharmacy network. Results of operations for the three and nine months ended September 30, 2018 reflect only Cigna’s legacy mail order pharmacy business.

The main driver of period over period increases in the financial information was the results from the Express Scripts’ business in 2019. The Health Services segment reflects strong performance, including customer growth, adjusted pharmacy scripts volume, specialty pharmacy care and management of supply chain.

### Integrated Medical Segment

The Integrated Medical segment includes the businesses previously reported in “Global Health Care” except as follows: 1) international health care products are now reported in the International Markets segment; 2) mail order pharmacy business is now reported in the Health Services segment; and 3) Medicare supplement business previously reported in “Global Supplemental Benefits” is now reported in Integrated Medical.

The business section of our 2018 Form 10-K (see the “Integrated Medical” section beginning on page 3) describes the various products and funding solutions offered by this segment, including the various revenue sources. As described in the introduction to Segment Reporting on page 60, performance of the Integrated Medical segment is measured using pre-tax adjusted income from operations. Key factors affecting profitability for this segment include:

customer growth;

revenues from integrated specialty products, including pharmacy services, sold to clients and customers across all funding solutions;

percentage of Medicare Advantage customers in plans eligible for quality bonus payments;

benefit expenses as a percentage of premiums (medical care ratio or “MCR”) for our insured commercial and government businesses; and

selling, general and administrative expense as a percentage of adjusted revenues (expense ratio).

### Results of Operations

*(In millions)*

| Financial Summary Three Months Ended September 30, Change Favorable 2019 2018 (Unfavorable) | Nine Months Ended September 30, 2019 2018 | Change Favorable (Unfavorable) |
| --- | ---: | ---: |
| Adjusted revenues **$9,148** $8,174 12% | **$27,311** $24,494 | 12% |
| Pre-tax adjusted income from operations **$953** $932 2% | **$3,113** $2,859 | 9% |
| Adjusted pre-tax margin **10.4%** 11.4% (100) bps | **11.4%** 11.7% | (30) bps |
| Medical care ratio **80.5%** 78.3% (220) bps | **80.3%** 78.3% | (200) bps |
| Expense ratio **23.2%** 24.5% 130 bps | **22.3%** 24.2% | 190 bps |
|  | **As of September 30,** |  |
| (In thousands) | **2019** **2018** | **% Change** |
| **Integrated Medical Customers** |  |  |
| Commercial risk | **2,078** 1,880 | 11% |
| Government | **1,374** 1,402 | (2)% |
| Total risk | **3,452** 3,282 | 5% |
| Service | **12,043** 12,019 | -% |
| Total | **15,495** 15,301 | 1% |
|  | **As of** **As of** |  |
| (In millions) | **September 30, 2019** **December 31, 2018** | **% Change** |
| Unpaid claims and claim expenses – Integrated Medical | $3,061 $2,697 | 13% |

### Three and Nine Months Ended September 30, 2019 versus Three and Nine Months Ended September 30, 2018

***Adjusted revenues.*** The increases for the three months and nine months ended September 30, 2019 compared with the same periods in 2018 reflect higher revenues in both our Commercial and Government operating segments. The increase in the Commercial segment reflects customer growth in our risk business as well as higher premium rates due to underlying medical cost trend. The increase in the Government segment reflects the addition of Express Scripts’ Medicare Part D business.

***Pre-tax adjusted income from operations.*** The increases for the three months and nine months ended September 30, 2019 compared with the same periods in 2018 reflect strong ongoing performance in our Commercial segment, including increased contributions from our commercial risk business and specialty products, partially offset by lower margins in our Individual business.

***Medical care ratio.*** As expected, the medical care ratio increased for the three months ended September 30, 2019 compared with the same period in 2018, primarily reflecting an additional business day in third quarter 2019 as compared to 2018, the pricing impact of the suspension of the health insurance industry tax in 2019, as well as a higher Individual business loss ratio. As expected, for the nine months ended September 30, 2019 compared with the same period in 2018, the medical care ratio increased reflecting the pricing impact of the suspension of the health insurance industry tax in 2019, business mix related to the addition of Express Scripts’ Medicare Part D business, as well as a higher Individual business loss ratio.

***Expense ratio.*** The expense ratio decreased for the three months and nine months ended September 30, 2019 compared with the same periods in 2018, primarily reflecting higher risk revenues and the suspension of the health insurance industry tax in 2019.

### Other Items Affecting Integrated Medical Results

### Unpaid Claims and Claim Expenses

Our unpaid claims and claim expenses liability was higher as of September 30, 2019 compared with December 31, 2018, primarily due to seasonality in our stop loss products, as well as customer growth.

### Medical Customers

Our medical customer base was higher at September 30, 2019 compared with the same period in 2018, primarily reflecting growth in our Select and Middle Market segments partially offset by lower membership in our National Accounts segment.

A medical customer is defined as a person meeting any one of the following criteria:

is covered under a medical insurance policy, managed care arrangement or service agreement issued by us;

has access to our provider network for covered services under their medical plan; or

has medical claims that are administered by us.

### International Markets Segment

The International Markets segment includes supplemental health, life and accident business previously reported in the “Global Supplemental Benefits” segment, except for our Medicare Supplement business that is now reported in the Integrated Medical segment and certain international businesses in run-off that are now reported in Group Disability and Other. International Markets also includes health care products previously reported in the former “Global Health Care” segment.

As described in the introduction to Segment Reporting on page 60, performance of the International Markets segment is measured using pre-tax adjusted income from operations. Key factors affecting pre-tax adjusted income from operations for this segment are:

premium growth, including new business and customer retention;

benefit expenses as a percentage of premiums (loss ratio);

selling, general and administrative expense and acquisition expense as a percentage of revenues (expense ratio and acquisition cost ratio); and

the impact of foreign currency movements.

### Results of Operations

*(In millions)*

| Financial Summary | Three Months Ended September 30, Change Favorable 2019 2018 (Unfavorable) |  | Nine Months Ended September 30, Change Favorable 2019 2018 (Unfavorable) |  |
| --- | ---: | ---: | ---: | ---: |
| Adjusted revenues | **$1,402** $1,326 | 6% | **$4,185** $4,011 | 4% |
| Pre-tax adjusted income from operations | **$194** $195 | (1)% | **$607** $615 | (1)% |
| Pre-tax adjusted margin | 13.8% 14.7% | (90) bps | 14.5% 15.3% | (80) bps |
| Loss ratio | 57.6% 57.1% | (50) bps | 56.8% 56.7% | (10) bps |
| Acquisition cost ratio | 13.0% 12.7% | (30) bps | 13.0% 12.8% | (20) bps |
| Expense ratio (excluding acquisition costs) | 19.0% 18.7% | (30) bps | 19.0% 18.3% | (70) bps |

64

### Three and Nine Months Ended September 30, 2019 versus Three and Nine Months Ended September 30, 2018

***Adjusted revenues*** increased mainly due to business growth in Europe, the Middle East and South Korea and the acquisition of OnePath Life in New Zealand in the fourth quarter of 2018. These increases are partially offset by unfavorable foreign currency movements.

***Pre-tax adjusted income from operations*** decreased due to unfavorable foreign currency movements along with higher benefit, acquisition and operating expenses, partially offset by the acquisition of OnePath Life and business growth in China.

The segment’s ***loss ratio*** was less favorable due to higher claims in Asia, largely offset by reserve updates.

The ***acquisition cost ratio*** increased due to higher amortization in South Korea. For the nine months ended September 30, 2019, higher acquisition expense in Taiwan also contributed to the increase, partially offset by the acquisition of OnePath Life.

The increase in the ***expense ratio*** (excluding acquisition costs) was driven by strategic investments for long-term growth and integration of OnePath Life.

### Other Items Affecting International Markets Results

South Korea is the single largest geographic market for our International Markets segment. For the nine months ended September 30, 2019, South Korea generated 37% of the segment’s adjusted revenues and 61% of the segment’s pre-tax adjusted income from operations. For the nine months ended September 30, 2019, our International Markets segment operations in South Korea represented 2% of our consolidated adjusted revenues and 6% of consolidated pre-tax adjusted income from operations.

### Group Disability and Other

Group Disability and Other includes the results of the business previously reported in the “Group Disability and Life” segment and “Other Operations” comprising the corporate-owned life insurance (“COLI”) business along with run-off of the following businesses: 1) reinsurance; 2) settlement annuity; and 3) the sold individual life insurance and annuity and retirement benefits businesses. In addition, certain international run-off business previously reported in the “Global Supplemental Benefits” segment is now reported in Group Disability and Other.

As described in the introduction of Segment Reporting on page 60, performance of Group Disability and Other is measured using pre-tax adjusted income from operations. Key factors affecting pre-tax adjusted income from operations are:

premium growth, including new business and customer retention;

net investment income;

benefit expenses as a percentage of premiums (loss ratio); and

selling, general and administrative expense as a percentage of revenues excluding net investment income (expense ratio).

### Results of Operations

*(In millions)*

| Financial Summary | Three Months Ended September 30, Change Favorable 2019 2018 (Unfavorable) |  | Nine Months Ended September 30, Change Favorable 2019 2018 (Unfavorable) |  |
| --- | ---: | ---: | ---: | ---: |
| Adjusted revenues | **$1,284** $1,262 | 2% | **$3,889** $3,815 | 2% |
| Pre-tax adjusted income from operations | **$143** $143 | -% | **$376** $420 | (10)% |
| Pre-tax adjusted margin | 11.1% 11.3% | (20) bps | 9.7% 11.0% | (130) bps |

### Three and Nine Months Ended September 30, 2019 versus Three and Nine Months Ended September 30, 2018

***Adjusted revenues*** increased, due to business growth in the group disability, life and voluntary businesses, partially offset by the continued run-off of international business and lower investment income.

***Pre-tax adjusted income from operations and margin*** is flat for the three months ended September 30, 2019 compared with the same period in 2018. For the nine months ended September 30, 2019 compared with the same period in 2018, the decrease is a result of unfavorable disability claims experience.

### Corporate

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and project costs and intersegment eliminations for products and services sold between segments. As discussed in the introduction to Segment Reporting on page 60, beginning in the first quarter of 2019, compensation cost for stock options is now recorded by the segments. Prior year results for Corporate were not restated to reflect this change.

*(In millions)*

| Financial Summary | Three Months Ended September 30, 2019 | 2018 | Change Favorable (Unfavorable) | Nine Months Ended September 30, 2019 | 2018 | Change Favorable (Unfavorable) |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Pre-tax adjusted loss from operations | **$(442)** | $(83) | N/M | **$(1,385)** | $(255) | N/M |

### Three and Nine Months Ended September 30, 2019 versus Three and Nine Months Ended September 30, 2018

***Pre-tax adjusted loss from operations*** was higher, reflecting interest expense on debt issued in the third quarter of 2018 to finance the Express Scripts acquisition and debt assumed from Express Scripts.

### INVESTMENT ASSETS

The following table presents our investment asset portfolio excluding separate account assets as of September 30, 2019 and December 31, 2018. Additional information regarding our investment assets is included in Notes 9, 10, 11 and 12 to the Consolidated Financial Statements.

*(In millions)*

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Debt securities | **$24,161** | $22,928 |
| Equity securities | **288** | 548 |
| Commercial mortgage loans | **1,886** | 1,858 |
| Policy loans | **1,352** | 1,423 |
| Other long-term investments | **2,363** | 1,901 |
| Short-term investments | **225** | 316 |
| Total | **$30,275** | $28,974 |

### Debt Securities

Investments in debt securities include publicly-traded and privately-placed bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor. These investments are classified as available for sale and are carried at fair value on our balance sheet. Additional information regarding valuation methodologies, key inputs and controls is included in Note 10 to the Consolidated Financial Statements. More detailed information about debt securities by type of issuer and maturity dates is included in Note 9 to the Consolidated Financial Statements.

The following table reflects our portfolio of debt securities by type of issuer as of September 30, 2019 and December 31, 2018.

*(In millions)*

|  | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Federal government and agency | **$757** | $710 |
| State and local government | **864** | 985 |
| Foreign government | **2,197** | 2,362 |
| Corporate | **19,809** | 18,361 |
| Mortgage and other asset-backed | **534** | 510 |
| Total | **$24,161** | $22,928 |

Our debt securities portfolio increased during the nine months of 2019 reflecting increased valuations due to decreases in market yields, partially offset by net sales and maturities. As of September 30, 2019, $21.7 billion, or 90% of the debt securities in our investment portfolio were investment grade (Baa and above, or equivalent) and the remaining $2.4 billion were below investment grade. The majority of the bonds that are below investment grade are rated at the higher end of the non-investment grade spectrum.

These quality characteristics have not materially changed from the prior year and are consistent with our investment strategy. Investments in debt securities are diversified by issuer, geography and industry as appropriate.

Foreign government obligations are concentrated in Asia, primarily South Korea, consistent with our risk management practice and local regulatory requirements of our international business operations. Corporate debt securities include private placement assets of $7.4 billion. These investments are generally less marketable than publicly-traded bonds; however yields on these investments tend to be higher than yields on publicly-traded bonds with comparable credit risk. We perform a credit analysis of each issuer and require financial and other covenants that allow us to monitor issuers for deteriorating financial strength and pursue remedial actions, if warranted.

In addition to amounts classified as debt securities in our Consolidated Balance Sheets, we participate in an insurance joint venture in China with a 50% ownership interest. This entity had an investment portfolio of approximately $7.4 billion supporting its business that is primarily invested in Chinese corporate and government debt securities. We account for this joint venture on the equity method of accounting and report it in other assets. There were no investments with a material unrealized loss as of September 30, 2019.

### Commercial Mortgage Loans

Our commercial mortgage loans are fixed rate loans, diversified by property type, location and borrower. Loans are secured by high quality commercial properties and are generally made at less than 70% of the property’s value at origination of the loan. Property value, debt service coverage, quality, building tenancy and stability of cash flows are all important financial underwriting considerations. We hold no direct residential mortgage loans and do not originate or service securitized mortgage loans.

Commercial real estate capital markets remain very active for well-leased, quality commercial real estate located in strong institutional investment markets. The vast majority of properties securing the mortgages in our mortgage loan portfolio possess these characteristics.

As of September 30, 2019, the $1.9 billion commercial mortgage loan portfolio consisted of approximately 65 loans that are generally in good standing. Given the quality and diversity of the underlying real estate, positive debt service coverage and significant borrower cash investment generally ranging between 30 and 40%, we remain confident that borrowers will continue to perform as expected under their contract terms.

### Other Long-term Investments

Other long-term investments of $ 2.4 billion as of September 30, 2019 included investments in securities limited partnerships and real estate limited partnerships as well as direct investments in real estate joint ventures. These entities typically invest in mezzanine debt or equity of privately-held companies (securities partnerships) and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher level of risk for higher expected returns. To mitigate risk, these investments are diversified across approximately 150 separate partnerships and approximately 75 general partners who manage one or more of these partnerships. Also, the underlying investments are diversified by industry sector or property type and geographic region. No single partnership investment exceeded 5% of our securities and real estate partnership portfolio.

### Problem and Potential Problem Investments

“Problem” bonds and commercial mortgage loans are either delinquent by 60 days or more or have been restructured as to terms, including concessions by us for modification of interest rate, principal payment or maturity date. “Potential problem” bonds and commercial mortgage loans are considered current (no payment is more than 59 days past due), but management believes they have certain characteristics that increase the likelihood that they may become problems.

The amount of problem or potential problem investments as of September 30, 2019 and December 31, 2018 was not material.

### Investment Outlook

Public equity markets rebounded during the first nine months of 2019, reflecting the continued strength of the U.S. economy. However, concerns related to trade and tariffs continue to contribute to financial market volatility. We continue to closely monitor global macroeconomic conditions and trends, including uncertainty caused by the United Kingdom’s process of exiting the European Union, and their potential impact on our investment portfolio. We expect continued volatility in certain sectors, such as retail, energy and natural gas. Future realized and unrealized investment results will be driven largely by market conditions that exist when a transaction occurs or at the reporting date. These future conditions are not reasonably predictable; however, we believe that the vast majority of our investments will continue to perform under their contractual terms. Based on our strategy to match the duration of invested assets to the duration of insurance and contractholder liabilities, we expect to hold a significant portion of these assets for the long term. Although future impairment losses resulting from interest rate movements and credit deterioration due to both investment-specific and the global economic uncertainties discussed above remain possible, we do not expect these losses to have a material adverse effect on our financial condition or liquidity.

### MARKET RISK

### Financial Instruments

Our assets and liabilities include certain financial instruments subject to the risk of potential losses from adverse changes in market rates and prices. Our primary market risk exposures are interest rate risk and foreign currency exchange rate risk. We encourage you to read this in conjunction with “Market Risk – Financial Instruments” included in the MD&A section of our 2018 Form 10-K. As of September 30, 2019, there were no material changes in our risk exposures from those reported in our 2018 Form 10-K.

## Market risk

As filed, 184 characters.

Information responsive to this item is contained under the caption “Market Risk” in Item 2 above, Management’s Discussion and Analysis of Financial Condition and Results of Operations.

## Controls and procedures

As filed, 1,492 characters.

Based on an evaluation of the effectiveness of Cigna’s disclosure controls and procedures conducted under the supervision and with the participation of Cigna’s management, Cigna’s Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, Cigna’s disclosure controls and procedures are effective to ensure that information required to be disclosed by Cigna in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to Cigna’s management, including Cigna’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

On December 20, 2018, Cigna acquired Express Scripts (see Note 4 to the Consolidated Financial Statements for additional information). As of September 30, 2019, management is in the process of evaluating and integrating the internal controls of the acquired Express Scripts business into the Company’s existing operations. Other than the controls enhanced or implemented to integrate the Express Scripts business, there have been no changes in Cigna’s internal controls over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, Cigna’s internal controls over financial reporting.

## Risk factors

As filed, 261 characters.

For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018.

Filed Oct 31, 2019.
Source: SEC EDGAR, the filing index for accession 0001739940-19-000012. Last ingested by Listed: Nov 5, 2026, 13:13 ET. No prices; not investment advice.
